Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founders and the current owners in connection with Altor’s investment in global fashion house Totême
Mandate

Vinge advises the founders and the current owners in connection with Altor’s investment in global fashion house Totême

May 21, 2021 M&A

Vinge advises the founders and other existing shareholders in connection with Altor Fund V’s investment in the global fashion house Totême. The founders will remain as majority shareholders and continue in their current roles in the development of Totême. Altor will support the founders and the company on its continued international growth journey.

Founded by Elin Kling and Karl Lindman in 2014 in New York City, Totême is a fast-growing fashion label in the modern luxury universe, widely known for their iconic uniforms. The company is headquartered in Stockholm with a strong Swedish heritage but with a true global presence. Sales are evenly split between Asia, North America and Europe, with a predominantly online presence via its own web shop and online retailers.

Vinge’s team consisted of Jonas Bergström, Karl Klackenberg and Hannah Kajlinger (M&A) as well as Viktoria Owetz Leyva (VDR Specialist).

 

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024